Editorial

A New Chapter

Digital Biomarkers is pleased to publish “Digital Medicine: A Primer on Measurement.” The piece by Andy Coravos and many of the leaders in the emerging field is an outstanding resource to help drive the field forward. The practical overview follows high-profile efforts to use digital tools to accelerate therapeutic development and improve clinical care.

Last year, the Clinical Trials Transformation Initiative, a public-private partnership that includes the US Food and Drug Administration (FDA), patient groups, technology companies, academic researchers, and pharmaceutical firms, produced recommendations on the use of mobile technologies in clinical trials. Some of that foundational work has been published in *Digital Biomarkers*. Other organizations, including the Critical Path Institute, are also bringing multiple diverse stakeholders together to capitalize on the opportunity these digital tools offer to transform health.

The authors of the primer are academics, entrepreneurs, and industry leaders. As such, the piece should be (as we hope the journal is) valuable to a diverse set of readers who come to the field from many different perspectives.

The primer also provides both novices and experts a guide for using digital tools to measure health in clinical care and in clinical trials. Readers new to the field will learn the basics of the field and the terminology and see case examples. The well initiated will better understand the current regulatory perspective on the use of digital biomarkers. All will appreciate and marvel at the beautiful illustrations.

Finally, we are pleased and honored that the piece is accompanying the announcement of the Digital Medicine (DiMe) Society. Many of the founders of this new multidisciplinary and trans-industry organization are also authors of the primer. We congratulate the DiMe Society on its founding and hope that *Digital Biomarkers*, which was created to “support a community that spans disciplines and industries,” can serve as a means for highlighting much of its future research.

In many ways, the primer and the founding of DiMe represent an ongoing maturation of a field that is still in its infancy. With continued contributions from DiMe and from all of you, we can start to realize the immense potential digital tools have for improving health.

E. Ray Dorsey, MD
Editor, *Digital Biomarkers*

Disclosure Statement

Dr. Dorsey is a member of DiMe, was part of the Clinical Trials Transformation Initiative’s mobile technologies effort, and works with the Critical Path Institute.